It converts nicotinamide (NA) into nicotinamide mononucleotide (NMN), which is further converted into nicotinamide adenine dinucleotide (NAD+) by nicotinamide mononucleotide adenylyltransferase (NMNAT).10 In contrast to the prevalence of p53 mutations in solid tumors, only 10% of hematological malignancies contain mutant p53.11 This gives rise to the important question of how malignancies, like leukemia, develop in the presence of p53, a strong tumor suppressor protein. Here, TP53 is linked to leukemia.